Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
antisenilin
- Development stage
- Unknown
- Lead developer
- Intellect Neurosciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Antisenilin is a proprietary platform technology developed by Intellect Neurosciences for the generation of monoclonal antibodies to treat Alzheimer's disease and other proteinopathies. The technology is designed to produce antibodies that specifically target the free N-terminus or C-terminus of the amyloid-beta (Aβ) peptide. A distinguishing feature of the Antisenilin platform is that the resulting antibodies do not recognize the Amyloid Precursor Protein (APP), which is intended to avoid potential toxicity or interference with the normal physiological functions of APP. This platform has been the basis for several high-profile clinical candidates through licensing agreements, including bapineuzumab (licensed to Elan and Wyeth, later Pfizer and Johnson & Johnson) and ponezumab (licensed to Pfizer).
- Brand names
- Antisenilin
- Other names
- Antisenilin technologyAntisenilin platform
02
Targets
Aβ (Amyloid-beta peptides and aggregates)
Beyond the preview
Go deeper on antisenilin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on antisenilin.